Edgewise Therapeutics, Inc., a leading muscle disease biopharmaceutical company, announced the dosing of the first patient in the phase 2 CIRRUS-HCM trial of EDG-7500. EDG-7500 is a novel oral, ...

BRISBANE, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to ...

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will study mavacamten as a therapeutic alternative to septal reduction therapy ...

EXPLORER-HCM Cardiac Imaging Data Presented at AHA 2020 Scientific Session with Simultaneous Publication in Circulation Mavacamten Treatment Resulted in Favorable Effect on Cardiac Structure -- ...

When a young athlete suddenly dies of a heart attack, chances are high that they suffer from familial hypertrophic cardiomyopathy (HCM). Itis the most common genetic heart disease in the US and ...

Edgewise announces completion of EDG-7500 CIRRUS-HCM phase 2 parts B & C and favourable interim safety results from the ongoing part D study in hypertrophic cardiomyopathy ...

Importantly, the experiments showed that treatment with an experimental small-molecule drug restored the balance of myosin arrangements and normalized the contraction and relaxation of both human and ...

Hypertrophic cardiomyopathy (HCM) is the most common genetic disease of the heart and a leading cause of sudden cardiac death in young people and athletes. Scientists have long known that the ...

Research using heart cells from squirrels, mice and people identifies an evolutionary mechanism critical for heart muscle function. Gene defect that affects a protein found in the heart muscle ...

Research using heart cells from squirrels, mice and people identifies an evolutionary mechanism critical for heart muscle function. Research using heart cells from squirrels, mice and people ...